Post on 27-May-2022
!"#$%&'(!)*+,(#-./0!1"2-&
)&2!34,(5(657(!83!(9:!;
&(3<(= >%&?(@!A; 0 &B,"'86
&(3<(= C%!%6D'9A; #6%C<8=!!A(=%&
&(3<(= 18$('! 2EF<'86
2G!3'(!4%#C9&BH# I&<F=&J&KL3M13'(!CK'9(0($J6D'<N0! !%OO(#@<D*C(<0!5DAP%0
GA"#@<D*C(<0!; $J(=%Q,(6D,$J%?6
4.C. 2543
DRUG USE EVALUATION OF
CEFTRIAXONE
AT BUMRUNGRAD HOSPITAL
MISS JINDAPORN TAPANEEYAKUL
MISS SIRILUK LERTSUWANNAWIN
MISS OUMAKORN HOSAKUL
A SPECIAL PROJECT SUBMITTED IN PARTIAL FULLFILMENT
OF THE REQUIREMENT FOR
THE BACHELOR DEGREE OF SCIENCE IN
PHARMACY
FACULTY OF PHARMACY
MAHIDOL UNIVERSITY
2000
!"#$%&'
()*+,-./0)123%0+4567)'*84.1.8)9:%0 0; <0)=9)0>?)@
!"#$%&'( )*"+,-./0, 1!&!02.3'( 40!15/6&&'$6!", 7/8$.& 9:;5./0 '0A0)%@!BC()D/>0: *&+<$ 8"=.$")!./0*
, 4>0!81&+ %/88$?.@&* , .8012.#!A 4&B7?4 &!C&/;? **
*%$D6!<$4%52<.&&8 D'-4%52<1$5)&( 8E$6!=,$02,8E!#0 **FG$,4%52<.&&8 9&?H,$I$0IJ$&/?&$3K&( "<0E<0"#F: 4LMN)&7-9L", .$&*&-48!".$&O<P,$
.$&*&-48!".$&O<P,$4*Q"I=I$==+R5J$D2CS7?4%52<.&O".$&*&-,/.)(E02..$&I&!I$0=$?4%52<.&&8LTR?4*Q"U"6D!#OE8;4HBR74H!R8D/'%$H<+6!)S7?V@P*G6, 4LMN)&7-9L" 4*Q",$*W!<+6"-O".0/;84LMM-9&5*7&!"&/;"=+R 3 LTR?8+X=Y!AD&7ID0/84<BZ7.6P$?=2Z?4<BZ7U.&8I6. U.&80I )07# "4<BZ7N8;HTR?77.L!4 " =J$OEP8+.$&O<P,$4LMN)&7-9L"7,;$?UH&;E0$,
7,;$?N&.[)$8E$.8+.$&O<P,$7,;$?N8;4E8$-587$ 5;?V0OEP4.!#.$&5!Z"4*0B7?D;$O<P ;$,O".$&&2.3$ &68N*\T?.$&UH&;.&- $,S7?4<BZ7#BZ7,$ O"9&?H,$I$0N#P 62)\/*&-5?D(S7?.$&1T.3$"+Z 4HBR7*&-48!"D6$84E8$-58S7?.$&O<P,$4LMN)&7-9L"O"
9&?H,$I$0IJ$&/?&$3K&( 9#,*&-48!"UII,P7"E02?)2Z?U);4#B7" 483$," – HX3%$D8 2543 U0-=J$.$&*&-48!"4*&+,I4=+,I.2I4.'](8$)&^$"O".$&O<P,$4LMN)&7-9L"=+R.J$E"#N6P9#,8+ J$"6"V@P*G6, 56 &$, LTR?UI;?4*Q"V@P*G6,4#[. ( 0 – 12 *_ ) J$"6" 20 &$, D!#4*Q"&P7,0- 35.71 U0-V@P*G6,V@POEC; ( 12 *_STZ"N* ) J$"6"
36 &$, D!#4*Q"&P7,0- 64.29
V0.$&1T.3$HI6;$ 8+D6$8N8;4E8$-58O".$&O<P,$4LMN)&7-9L"=2Z?O"V@P*G6,4#[.U0-O"V@P*G6,V@POEC; 9#,O"V@P*G6,4#[.8+ J$"6" 18 &$, D!#4*Q"&P7,0- 90.00 U0-O"V@P*G6,V@POEC;8+ J$"6" 30 &$,
D!#4*Q"&P7,0- 83.33 LTR?D6$8N8;4E8$-58=+RHIDB7 .$&O<P,$4LMN)&7-9L"O"SP7I;?O<P=+RN8;N#P8+.J$E"#N6P U0-&-,-460$O".$&O<P,$"P7,.6;$=+R.J$E"#N6P U0-48BR7*&-48!"V0.$&&2.3$E02? $..$&O<P,$ 9#,H! $&'$ $. 7/'E%@8!, 48[#40B7#S$6 U0-.$&.J$ 2#4<BZ7UID=+4&+,HI6;$ V@P*G6,5;6"OEC;N8;8+NSPE02?.$&O<P,$ 5;6"48[#40B7#S$6U0-.$&.J$ 2#UID=+4&+,N8;5$8$&\"J$8$*&-48!"V0.$&&2.3$N#P4"BR7? $.N8;8+.$&52R?)&6 E02? $.O<P,$4LMN)&7-9L"
V0S7?.$&1T.3$<+ZOEP4E["6;$ U8PV@P*G6,5;6"OEC; -8+V0.$&&2.3$=+R#+E02?.$&O<P,$4LMN)&7-9L" U);48BR7H! $&'$D6$84E8$-58O".$&O<P4LMN)&7-9L"O"9&?H,$I$0IJ$&/?&$3K&(HI6;$5;6"E"TR?,2?4*Q".$&O<P,$7,;$?N8;584E)/58V0)$84.'](8$)&^$".$&O<P,$ U0-7$ =J$OEP4.!#.$&5!Z"4*0B7?D;$O<P ;$, &68N*\T?.$&4.!#V0.&-=IO".$&=J$OEP4<BZ7#BZ7,$4&[6STZ"#P6,
!
Abstract
Drug use evaluation of ceftriaxone at Bumrungrad hospital
Jindaporn tapaneeyakul, Siriluk lertsuwannawin, Oumakorn hosakul
Project advisor: Preecha Montakantikul*, Chalermsri Pummangura
*,
Kamolsak Ruengjaroenrung**
*Department of Pharmacy, Mahidol University
**Pharmacy Department, Bumrungrad Hospital
Keyword: Ceftriaxone, Drug use evaluation
Drug use evaluation (DUE) is an important role of
pharmacist in implementation of new concept of pharmaceutical
care. This would contribute to quality of life of patients. Ceftriaxone is a beta-lactam antibiotic in the group called third generation
cephalosporins which has broad spectrum activity. It is active against most gram-positive, gram-
negative aerobic and anaerobic bacteria. However, inappropriate use of the medication may
result in high expenditures in treatment course and spreading of resistant organisms.
The purpose of this study was to retrospectively evaluate the rational use of
ceftriaxone in Bumrungrad hospital during April-May 2000 by comparing with standard criteria for
ceftriaxone utilization. There were 56 cases with 20 cases (35.71%) of pediatric patients (0-12
years ) and 36 cases (64.29%) of adult and adolescent patients ( 12 years).
The results showed that the inappropriate drug use in pediatric patients was 18
cases (90.00%) and adult patients was 30 cases (83.33%). The majority of inappropriateness
were indication and duration of drug therapy. Outcome of therapy in terms of temperature, white
blood cell count (WBC) and bacterial eradication, showed that most patients became afebrile after
ceftriaxone therapy. WBC normalization and bacterial eradication could not be evaluated because
of no repeated test available.
In conclusion, the result of this study indicated that although most patients have
good outcome after ceftriaxone therapy, the use of ceftriaxone was not completely appropriate
which may result in high expenditures in treatment course and spreading of resistant organism.